• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.
 

Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum.

Options
  • Details
  • Files
BORIS DOI
10.48350/160451
Publisher DOI
10.1093/eurheartj/ehab642
PubMed ID
34624084
Description
Intravascular thrombus formation and embolization are among the most frequent events leading to a number of cardiovascular conditions with high morbidity and mortality. The underlying causes are stasis of the circulating blood, genetic and acquired coagulation disorders, and reduced antithrombotic or prothrombotic properties of the vascular wall (Virchow's triad). In the venous system, intravascular thrombi can cause venous thrombosis and pulmonary and even peripheral embolism including ischaemic stroke [through a patent foramen ovale (PFO)]. Thrombi in the left atrium and its appendage or ventricle form in the context of atrial fibrillation and infarction, respectively. Furthermore, thrombi can form on native or prosthetic aortic valves, within the aorta (in particular at sites of ulcers, aortic dissection, and abdominal aneurysms), and in cerebral and peripheral arteries causing stroke and critical limb ischaemia, respectively. Finally, thrombotic occlusion may occur in arteries supplying vital organs such the heart, brain, kidney, and extremities. Thrombus formation and embolization can be managed with anticoagulants and devices depending on where they form and embolize and on patient characteristics. Vitamin K antagonists are preferred in patients with mechanical valves, while novel oral anticoagulants are first choice in most other cardiovascular conditions, in particular venous thromboembolism and atrial fibrillation. As anticoagulants are associated with a risk of bleeding, devices such as occluders of a PFO or the left atrial appendage are preferred in patients with an increased bleeding risk. Platelet inhibitors such as aspirin and/or P2Y12 antagonists are preferred in the secondary prevention of coronary artery disease, stroke, and peripheral artery disease either alone or in combination depending on the clinical condition. A differential and personalized use of anticoagulants, platelet inhibitors, and devices is recommended and reviewed in this article.
Date of Publication
2022-03-07
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Keyword(s)
Atrial fibrillation Coagualtion Coronary artery disease Dual antiplatelet therapy Left atrial occlusion NOAC Peripheral arterial disease Platelets Pulmonary embolism
Language(s)
en
Contributor(s)
Lüscher, Thomas F
Davies, Allan
Beer, Juerg H
Valgimigli, Marco
Nienaber, Christoph A
Camm, John A
Baumgartner, Iris
Universitätsklinik für Angiologie
Diener, Hans-Christoph
Konstantinides, Stavros V
Additional Credits
Universitätsklinik für Angiologie
Series
European heart journal
Publisher
Oxford University Press
ISSN
1522-9645
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: dd892c [ 9.04. 8:30]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo